Bruce Booth Sells 37,746 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Key Points

• Director Bruce Booth sold 37,746 shares of Sionna Therapeutics stock on October 3rd, amounting to $1,132,380 at an average price of $30.00.
• Following the transaction, Booth's ownership decreased by 4.57%, leaving him with 787,527 shares valued at approximately $23.6 million.
• Sionna Therapeutics stock has recently experienced analyst ratings ranging from "Strong Buy" to "Sell," with a consensus rating of "Moderate Buy" and an average price target of $38.00.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Bruce Booth sold 37,746 shares of the business's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $30.00, for a total value of $1,132,380.00. Following the completion of the sale, the director directly owned 787,527 shares of the company's stock, valued at $23,625,810. The trade was a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Bruce Booth also recently made the following trade(s):

• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $353,410.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.06, for a total transaction of $372,383.28.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.09, for a total transaction of $1,989,099.45.

Sionna Therapeutics Trading Down 2.2%

SION traded down $0.64 on Tuesday, hitting $28.61. 153,162 shares of the company were exchanged, compared to its average volume of 207,408. The business's fifty day moving average is $23.25 and its 200 day moving average is $17.45. Sionna Therapeutics, Inc. has a fifty-two week low of $7.26 and a fifty-two week high of $30.60.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.27.

Analyst Upgrades and Downgrades

SION has been the subject of several recent analyst reports. Jones Trading assumed coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a "buy" rating and a $46.00 price target for the company. Weiss Ratings reissued a "sell (d)" rating on shares of Sionna Therapeutics in a research report on Saturday, September 27th. Royal Bank Of Canada initiated coverage on shares of Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price objective for the company. Wall Street Zen upgraded Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Finally, Raymond James Financial began coverage on Sionna Therapeutics in a research report on Tuesday, September 2nd. They set a "strong-buy" rating and a $45.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $38.00.

Hedge Funds Weigh In On Sionna Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics in the 2nd quarter valued at about $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sionna Therapeutics during the 2nd quarter worth approximately $45,000. Virtus Investment Advisers LLC bought a new stake in Sionna Therapeutics in the 2nd quarter valued at $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Sionna Therapeutics during the 2nd quarter worth $117,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $118,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.